Press Releases

04.28.22
OpGen to Provide Business Update and Financial Results for the First Quarter 2022 on May 12th at 4:30 p.m. Eastern Time
04.25.22
OpGen’s Subsidiary Curetis and European Investment Bank Plan to Restructure Debt Repayment
04.20.22
OpGen’s Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally
04.06.22
OpGen’s subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
04.05.22
OpGen Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel
03.29.22
OpGen Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
03.15.22
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2021 on March 29th at 4:30 p.m. Eastern Time
02.10.22
OpGen Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology
02.10.22
OpGen Announces Successful Completion of Unyvero A30 Development Milestone
01.18.22
OpGen to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022